Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Silo enters into commercial evaluation license agreement for next generation liposomes
Brings 25 years of global operations and supply chain experience to Piramal
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Atik Cameras launches ChemiMOS; A 9MP CMOS camera for scientific applications
The company is now introducing the product into the India pharmaceutical market.
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Subscribe To Our Newsletter & Stay Updated
